Provided By GlobeNewswire
Last update: Nov 5, 2024
FORT LEE, N.J., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the third quarter of 2024 and provided an update on recent business progress.
Read more at globenewswire.comNASDAQ:NVCT (6/9/2025, 11:51:17 AM)
8.65
-0.2 (-2.26%)
Find more stocks in the Stock Screener